Madrigal Pharmaceuticals, Inc. (MDGL)
MDGLNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$432.79
+33.16 (+8.30%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $10.05bn
- P/E
- –
- EPS, last 4 quarters
- $-5.98
- Dividend yield
- –
- Day range
- –
- 52-week range
- $353.54 to $615.00
- Average volume
- 359.2k
- Previous close
- $399.63
Analysts
9 coveringBuy8 buy, 1 hold, 0 sell
Targets a year out average $699.10, +61.5% from here
Earnings
next estimate $1.34Next report
Dec 2025
-6525.0%
Mar 2026
+10.0%
Jun 2026
+22.0%
Sep 2026
+267.9%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $321.08m | $311.34m | $364.25m | $431.27m |
| Gross profit | $296.63m | $284.49m | $324.25m | $393.45m |
| Operating income | -$59.61m | -$92.72m | -$56.31m | $55.99m |
| Net income | -$58.58m | -$94.39m | -$57.94m | $55.44m |
Last four quarters: revenue $1.43bn, margin -10.9%, free cash flow -$168.65m
News
8 latest- Madrigal (MDGL) Q3 2026 Earnings Call TranscriptThe Motley Fool · 6 days ago
- What Madrigal Pharmaceuticals (MDGL) Said on Its Q3 Earnings CallMarketBeat · 6 days ago
- Madrigal Swings To Q3 Profit As Rezdiffra Sales Jump 50% RTTNews · 6 days ago
- Madrigal Pharmaceuticals, Inc. Reports Third-Quarter 2026 Net Revenues of $431.3 million and Achieves First Quarter of ProfitabilityFintel · 6 days ago
- Madrigal (MDGL) Q3 Earnings and Revenues Beat EstimatesZacks · 7 days ago
- Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out forZacks · Oct 28, 2026
- Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should KnowZacks · Oct 27, 2026
- Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?Zacks · Oct 7, 2026
The company
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR- agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- madrigalpharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.